Anti-PRL-3 Monoclonal Antibody PRL3-zumab clinical trials
Its developmentBy Intra-IMMUSG Pte, step by step4 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PRL-3 Monoclonal Antibody PRL3-zumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PRL-3 Monoclonal Antibody PRL3-zumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- PRL3-ZUMAB
- 6
Studies by the year they started
6 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Intra-IMMUSG Pte Ltd (4) · National University Hospital, Singapore (1) · National Cancer Centre, Singapore (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test Anti-PRL-3 Monoclonal Antibody PRL3-zumab, phase 3 first.
- Dec 2026Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor PatientsPhase 2/3 · Intra-IMMUSG Pte Ltd
- Dec 2026A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid TumorsPhase 2 · Intra-IMMUSG Pte Ltd
- Feb 2027A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)Phase 1/2 · Intra-IMMUSG Pte Ltd
- Feb 2027A First-in-Human Study of PRL3-ZUMABPhase 1 · National University Hospital, Singapore
Studies
Open first, then newest update. How each study uses Anti-PRL-3 Monoclonal Antibody PRL3-zumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)RecruitingPhase 1/2Intra-IMMUSG Pte LtdNCT07547228Written as PRL3-ZUMABHow we know
- Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor PatientsRecruitingPhase 2/3Intra-IMMUSG Pte LtdNCT07290088Written as PRL3-ZUMABHow we know
- Phase II Study of PRL3-ZUMAB in Advanced Solid TumorsCompletedPhase 2National Cancer Centre, SingaporeNCT04118114Written as PRL3-zumabHow we know
- PRL3-Zumab in Patients With Advanced Solid TumorsActive, not recruitingPhase 2Intra-IMMUSG Pte LtdNCT07541001Written as PRL3-ZUMABHow we know
- A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid TumorsActive, not recruitingPhase 2Intra-IMMUSG Pte LtdNCT04452955Written as PRL3-zumabHow we know
- A First-in-Human Study of PRL3-ZUMABActive, not recruitingPhase 1National University Hospital, SingaporeNCT03191682Written as PRL3-ZUMABHow we know